论文部分内容阅读
目的：分析AML－M4、M5患者的临床和免疫学特征。万法：总结了75例患者的血液学和临床特征，并用活细胞间接免疫荧光法检测了其中39例患者的细胞免疫表型，着重分析了CD7+AML在这二类AML中的发生率、临床特征及预后。结果：这两类白血病的HLA－DR、CD38、CD34阳性率很高，分别为91．43％，85．19％和65．63％，CD7阳性率为35．90％；结论：M4、M5这二种亚型有不同于其它AML亚型的临床，血液学和生物学特征。
Objective: To analyze the clinical and immunological features of AML-M4 and M5 patients. Wan Fa: We summarized the hematological and clinical features of 75 patients and examined the cellular immune phenotypes of 39 patients with live cell indirect immunofluorescence. We focused on the incidence of CD7+ AML in these two types of AML. Clinical features and prognosis. Results: The positive rates of HLA-DR, CD38 and CD34 in these two types of leukemia were 91.43%, 85.19% and 65.63%, respectively. The positive rate of CD7 was 35.90%. Conclusion: M4, M5 These two subtypes have clinical, hematological, and biological characteristics that are different from other AML subtypes.